0000000
levaes is currently available in limited geographies. Please contact us if you would like more information.
Contact Us

Leadership Team

Marc Beer
Co-Founder, Chairman & CEO

Marc brings more than 25 years of development and commercialization experience in biotechnology, pharmaceuticals, devices, and diagnostics. Marc founded Renovia with Ramon Iglesias, MD and Yolanda Lorié in August 2016 and successfully closed a Series A financing with leading healthcare venture capital funds.

Marc is the former Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID® (lomitapide) was approved by the US Food and Drug Administration in December 2012 for homozygous familial hypercholesterolemia. During his tenure, JUXTAPID obtained marketing approval in 36 countries. Additionally, Aegerion acquired its second product, MYALEPT® (metreleptin), approved in the US for generalized lipodystrophy, an ultra-rare disease.

In April 2000, Marc became the Founding CEO of ViaCell (NASDAQ: VIAC), a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc’s leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (NYSE: PKI).

While serving as CEO of ViaCell, Marc also served as a member of the board of directors of Erytech Pharma (NASDAQ: ERYP), a publicly traded biopharmaceutical company. Prior to ViaCell, Marc held various positions within Genzyme, most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing rare disease populations on a global scale.

Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (NYSE: ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board.

Marc was also Founding Chairman of the board of directors and chairman of the compensation committee of Good Start Genetics, Inc., recently acquired by InVitae (NASDAQ: NVTA). He is the Founding Chairman of the board, chairman of the compensation committee and member of the audit committee of Minerva Neurosciences Inc. (NASDAQ: NERV); and a member of the Miami University Business Advisory Council and previously a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council. Marc holds a BS from Miami University (Ohio).

William Dull
Chief Commercial Officer

William serves as Renovia’s Chief Commercial Officer overseeing global commercial and company operations. William brings more than 30 years of senior leadership experience as a life science executive. As an accomplished entrepreneur, he has built, developed and led high-performing integrated teams and partnerships from early-stage research and development to successful domestic and international commercialization. He has built businesses and advanced value propositions to deliver significant revenue growth for start-up and mid-sized biopharmaceutical companies and biologic manufacturing organizations.

William joined Renovia from Aegerion Pharmaceuticals where he developed innovative solutions that solved complex patient problems. At Aegerion he led global marketing, commercial operations, consumer engagement and training in the launch of two therapeutic brands. Prior to joining Aegerion, William held global executive positions of increasing responsibilities in strategic planning, sales and marketing, patient advocacy and new product commercialization for therapeutics, manufacturing operations and genetic testing. William holds a Bachelor of Science degree in Business Administration from Georgia State University.

Dr. Samantha (Mandy) Pulliam, MD
Chief Medical Officer

Dr. Pulliam joins Renovia from the University of North Carolina at Chapel Hill School of Medicine where she has been an Assistant Professor of Obstetrics and Gynecology and Division Director for Urogynecology and Pelvic Reconstructive Surgery. Prior to her work at UNC, Dr. Pulliam was the Associate Director of Female Pelvic Medicine and Reconstructive Surgery at Massachusetts General Hospital. Pulliam received her bachelor of science in biology from Duke University in 1990, and her doctor of medicine from Wake Forest University in 1998. She completed her residency in obstetrics and gynecology at Massachusetts General Hospital/Brigham and Women’s Hospital in 2003 and her fellowship in female pelvic medicine and reconstructive surgery at Mount Auburn Hospital in 2006.

In addition to her clinical expertise, she brings an extensive background in clinical research and has published over 50 peer reviewed research papers and abstracts. In addition, she is an inaugural member of the AUGS Quality Improvement Outcomes Research Network, whose goal is to provide data regarding quality of care in FPMRS. Dr. Pulliam has led Renovia’s Medical Advisory Board and her insights, guidance and leadership has accelerated our clinical research and development efforts

José Bohorquez, PhD
Chief Scientific Officer

José Bohorquez, PhD has more than 15 years of experience leading technology and product development. His areas of expertise include biosensors and medical devices, integrated circuits, and the Internet of Things (IoT). Previously, Dr. Bohorquez was co-founder and CEO of Myolex (a.k.a. Skulpt), where he led the development and commercialization of one medical device and two award-winning consumer devices. He was also previously a Principal Consultant at T-Var Semiconductor and a Senior Engineer at Bitwave Semiconductor. He has co-authored fifteen peer-reviewed publications, four issued patents, and ten pending patents. Dr. Bohorquez has a Bachelor’s and Master’s degree in electrical engineering from the University of Florida (suma cum laude). He also holds a PhD in electrical engineering and computer science from MIT with a minor in business administration from the Sloan School of Management. He has received several honors and awards including the MIT Presidential Fellowship, the University of Florida Gator100 Award, two CES Innovation Awards, and the Best of What’s New Award from Popular Science. Dr. Bohorquez is a US citizen and is fluent in English and Spanish.

Jessica McKinney, PT, MS, CMPT
Vice President of Medical Affairs and Clinical Advocacy

Ms. McKinney serves as Director of The Center for Pelvic and Women’s Health for Marathon Physical Therapy & Sports Medicine, a program dedicated to physical therapy, education and wellness of men, women, and girls with an emphasis on pelvic and maternal health. She is an active clinician, speaker, educator, and mentor.  Since 2009, she has pursued and developed emerging programs in obstetric fistula rehabilitation, pelvic and women’s health in low-income countries, working with organizations, such as the FistulaCare Plus project of EngenderHealth, Panzi Hospital and Foundation, Global Strategies and HEAL Africa in the Democratic Republic of Congo. Her work is dedicated to promoting multidisciplinary collaboration, and promoting access to care, program development and capacity building in pelvic and women’s health physiotherapy. Ms. McKinney is a 2000 graduate of Virginia Commonwealth University, earning a Master’s of Science in Physical Therapy. She is co-author of several papers, abstracts, academic videos, and a book chapter and is involved in ongoing research projects involving pelvic pain, global and domestic maternal health, and surgical ergonomics and recently co-founded a public health and physical therapy consulting agency dedicated to improving women’s and girls’ health domestically and internationally.